NCT00703482

A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 278 (actual)
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 40 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to study the effect of different combinations of fenofibrate and coenzyme Q10 on ventricular diastolic function in patients with Type II diabetes

Conditions

• Patients With Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Fenofibrate/CoQ10	Fenofibrate pbo/CoQ10 placebo
DRUG	Fenofibrate/CoQ10	Fenofibrate pbo/CoQ10 200 mg
DRUG	Fenofibrate/CoQ10	Fenofibrate 160mg/CoQ10 placebo
DRUG	Fenofibrate/CoQ10	Fenofibrate 80/CoQ10 100 mg
DRUG	Fenofibrate/CoQ10	Fenofibrate 160mg/CoQ10 100 mg
DRUG	Fenofibrate/CoQ10	Fenofibrate 80 /CoQ10 200 mg
DRUG	Fenofibrate/CoQ10	Fenofibrate 160mg/CoQ10 200 mg

Timeline

• Start date: 2003-05-01
• Primary completion: 2004-09-01
• Completion: 2004-09-01
• First posted: 2008-06-23
• Last updated: 2008-06-25

Locations

3 sites across 1 country: Australia